FENNEC PHARMACEUTICALS INC's ticker is FENC and the CUSIP is 31447P100. A total of 58 filers reported holding FENNEC PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $52 | -63.6% | 8,368 | -35.0% | 0.00% | – |
| Q1 2024 | $143 | -49.3% | 12,876 | -48.7% | 0.00% | – |
| Q4 2023 | $282 | +984.6% | 25,075 | +624.7% | 0.00% | – |
| Q3 2023 | $26 | -18.8% | 3,460 | -4.8% | 0.00% | – |
| Q2 2023 | $32 | -60.5% | 3,635 | -62.5% | 0.00% | – |
| Q1 2023 | $81 | -9.0% | 9,697 | +4.7% | 0.00% | – |
| Q4 2022 | $89 | -99.6% | 9,260 | +249.7% | 0.00% | – |
| Q3 2021 | $25,000 | +19.0% | 2,648 | -11.6% | 0.00% | – |
| Q2 2021 | $21,000 | -81.4% | 2,994 | -83.5% | 0.00% | – |
| Q1 2021 | $113,000 | +113.2% | 18,194 | +159.0% | 0.00% | – |
| Q4 2020 | $53,000 | -11.7% | 7,024 | -28.3% | 0.00% | – |
| Q3 2020 | $60,000 | -40.0% | 9,803 | -18.1% | 0.00% | – |
| Q2 2020 | $100,000 | +4900.0% | 11,965 | +2103.5% | 0.00% | – |
| Q2 2019 | $2,000 | -88.2% | 543 | -84.1% | 0.00% | – |
| Q1 2019 | $17,000 | -55.3% | 3,416 | -26.2% | 0.00% | – |
| Q3 2018 | $38,000 | +375.0% | 4,631 | +458.0% | 0.00% | – |
| Q2 2018 | $8,000 | – | 830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 630,000 | $3,056,000 | 0.85% |
| Southpoint Capital Advisors LP | 3,997,214 | $19,386,000 | 0.82% |
| 683 Capital Management, LLC | 971,351 | $4,711,000 | 0.43% |
| Avoro Capital Advisors LLC | 1,105,999 | $5,364,000 | 0.23% |
| Eventide Asset Management | 720,000 | $3,492,000 | 0.12% |
| Granahan Investment Management | 410,932 | $1,993,000 | 0.11% |
| Zebra Capital Management LLC | 17,568 | $85,000 | 0.04% |
| Hartford Financial Management Inc. | 12,300 | $60,000 | 0.02% |
| OXFORD ASSET MANAGEMENT LLP | 84,750 | $411,000 | 0.01% |
| Wealthspire Advisors, L.P. | 9,500 | $46,000 | 0.00% |